Project 2: Therapeutic Targeting of the Ras Pathway by Nanoparticle Delivery of siRNA Three types of nanoparticles, i.e. LPD, LCP and PRINT, will be used to deliver siRNA to lung cancer cells in a genetically engineered mouse (GEM) model (Kim, co-PI). LPD is a self-assembled, core/membrane nanoparticle, the unique feature of which is the high density ofthe surface grafted PEG chains. Previous work by Huang (co-PI) has shown that LPD accumulates in xenografted human lung tumors at the level of 60-80 % injected dose per g of tissue with minimal uptake by liver and spleen. Three daily i.v. injections of LPD containing siRNA effectively silenced the tumor target gene expression. LCP is similar in structure to LPD, but the core is replaced with calcium phosphate amorphous nanoprecipltate that dissolves in the endosomal acidic pH to release its cargo and swells and bursts the endosomes. The PRINT (DeSimone, co-1) are topdown manufactured nanoparticles In which any carrier and cargo materials can be readily loaded. Dr. DeSimone has shown that siRNA can be successfully loaded in PRINT and delivered to tumor cells for gene silencing. A salient feature of the project is the KRas driven lung cancer GEM. sIRNAs designed against Ras and Ras effector pathways will be tested and delivered as therapeutics. This is particularly significant, because Ras is considered an undruggable target by conventional medicinal chemistry approaches. Furthermore, gemcitabine mono (or di-) phosphate (GMP or GDP), metabolites of gemcitabine will be formulated in LCP nanoparticles and delivered to the tumor cells by itself or together with siRNA. This is a novel approach that takes advantage of the large cargo capacity of these nanoparticles. The project is milestone driven in that by the end of the year 3, at least one nanoparticle formulation will be identified for therapy, pharmacokinetics and toxicity studies In GEM. The formulation should be ready for detailed characterization and toxicity studies in collaboration with Nanotechnology Characterization Lab at NCI for further translational development.
Lung cancer Is a major cancer threat In human. The project will develop nanoparticle formulations for delivering siRNA and/or gemcitabine to a genetically engineered mouse model that is driven by KRas oncogene. This is a realistic approach to treat human lung cancer.
|Rocca, Joseph Della; Werner, Michael E; Kramer, Stephanie A et al. (2015) Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy. Nanomedicine 11:31-8|
|Friedman, Adam D; Kim, Dongwook; Liu, Rihe (2015) Highly stable aptamers selected from a 2'-fully modified fGmH RNA library for targeting biomaterials. Biomaterials 36:110-23|
|Zhang, Lei; Yuan, Hong; Inscoe, Christina et al. (2014) Nanotube x-ray for cancer therapy: a compact microbeam radiation therapy system for brain tumor treatment. Expert Rev Anticancer Ther 14:1411-8|
|Gharpure, Kshipra M; Chu, Kevin S; Bowerman, Charles J et al. (2014) Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther 13:1750-7|
|Liu, Yang; Hu, Yunxia; Huang, Leaf (2014) Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials 35:3027-34|
|Miao, Lei; Guo, Shutao; Zhang, Jing et al. (2014) Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct Mater 24:6601-6611|
|Zhang, Jing; Miao, Lei; Guo, Shutao et al. (2014) Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release 182:90-6|
|Zhang, Lei; Yuan, Hong; Burk, Laurel M et al. (2014) Image-guided microbeam irradiation to brain tumour bearing mice using a carbon nanotube x-ray source array. Phys Med Biol 59:1283-303|
|Guo, Shutao; Miao, Lei; Wang, Yuhua et al. (2014) Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release 174:137-42|
|Smith, Matthew J; Brown, Jared M; Zamboni, William C et al. (2014) From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system. Toxicol Sci 138:249-55|
Showing the most recent 10 out of 73 publications